CGT9486 + pexidartinib

**CGT9486 + pexidartinib** is an investigational combination therapy composed of two oral small molecule inhibitors. **CGT9486** (formerly PLX9486, also known as bezuclastinib) is a selective tyrosine kinase inhibitor targeting *KIT* mutations that drive cancer cell growth, particularly in advanced solid tumors such as gastrointestinal stromal tumors (GIST)[3][5]. **Pexidartinib** (PLX3397, branded as Turalio) is an approved kinase inhibitor that principally targets the *Colony stimulating factor 1 receptor (CSF1R)*, used in the treatment of tenosynovial giant cell tumor and investigated for other indications[2][4][6][8]. The rationale for combining these drugs is to more effectively block multiple oncogenic pathways involved in tumor progression and resistance, particularly those driven by mutations in *KIT* and activation of *CSF1R*.

Brand names

Turalio

Other names

CGT9486CGT-9486CGT 9486bezuclastinibPLX9486PLX-9486PLX 9486PLX3397PLX-3397PLX 3397pexidartinib